Jump to main content
Jump to site search


Polymeric nanovesicle as simultaneous delivery platform with Doxorubicin conjugation and Elacridar encapsulation for enhanced treatment of multidrug-resistant breast cancer

Abstract

Multidrug resistance (MDR) is one of the major obstacles to the successful chemotherapy of cancer. Overexpression of drug efflux transporters such as P-glycoprotein (P-gp) is an important factor responsible for MDR. In this study, a novel copolymer methoxy-poly(ethylene glycol)-poly[(N-(6-hydroxyhexyl)-g-doxorubicin-aspartamide)-(β-benzyl-L-aspartate)] (mPEG-P[Asp(HPA-g-DOX)-BLA)] was synthesized and utilized to assemble into nanovesicle with hydrophilic P-gp inhibitor of elacridar hydrochloride (Ela) encapsulated into the aqueous lumen. Doxorubicin (DOX) was covalently conjugated onto the polymer chain via a pH-cleavable amide linkage, leading to a pH responsive DOX release as well as disintegration of nanovesicle in the lysosome of tumor cells. In vitro studies demonstrated that the DOX and Ela co-delivered nanovesicles showed superior cytotoxicity and enhanced anti-tumor ability than single DOX-delivery nanosystem in MCF-7/ADR cancer, which could be attributed to the P-gp bioactivity inhibition as investigated by cell immunofluorescence assay. In vivo studies showed that the polymeric nanovesicles effectively accumulated at the tumor site and the co-delivered DOX and Ela effectively suppressed the growth of MCF-7/ADR tumor. All the results indicated that the acid-liable nanovesicles had the synergistic effect to enhance antitumor efficacy for multidrug-resistant breast cancer treatment.

Back to tab navigation

Supplementary files

Publication details

The article was received on 13 Jul 2018, accepted on 09 Oct 2018 and first published on 11 Oct 2018


Article type: Paper
DOI: 10.1039/C8TB01829D
Citation: J. Mater. Chem. B, 2018, Accepted Manuscript
  •   Request permissions

    Polymeric nanovesicle as simultaneous delivery platform with Doxorubicin conjugation and Elacridar encapsulation for enhanced treatment of multidrug-resistant breast cancer

    H. Xiao, J. He, X. Li, B. Li, L. Zhang, Y. Wang, C. Du and X. Shuai, J. Mater. Chem. B, 2018, Accepted Manuscript , DOI: 10.1039/C8TB01829D

Search articles by author

Spotlight

Advertisements